Several PARP-targeted agents, including niraparib, talazoparib, pamiparib, and fluzoparib, are currently approved for the treatment of malignant tumors, such as pancreatic cancer, breast cancer, and prostate cancer [69]. Here, PARP1 is linked to breast cancer.